Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Hormone-sensitive Prostate Cancer (mHSPC)”

58 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 58 results

Not applicableStudy completedNCT06498921
What this trial is testing

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 106
Not applicableActive Not RecruitingNCT05901649
What this trial is testing

The Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Janssen-Cilag Ltd. 504
Large-scale testing (Phase 3)Looking for participantsNCT06177015
What this trial is testing

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Who this might be right for
Metastatic Prostate CancerIntermitent Anti-androgen Therapy
The First Affiliated Hospital with Nanjing Medical University 200
Not applicableLooking for participantsNCT07406282
What this trial is testing

Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-Sensitive Prostate Cancer
Bayer 1,400
Early research (Phase 1)Not Yet RecruitingNCT06099990
What this trial is testing

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd. 660
Not applicableStudy completedNCT06072196
What this trial is testing

Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Prostatic Neoplasms
Pfizer 3,017
Not applicableActive Not RecruitingNCT06010914
What this trial is testing

Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 100
Post-approval studies (Phase 4)Active Not RecruitingNCT06479187
What this trial is testing

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerMetastatic Hormone-sensitive Prostate Cancer (mHSPC)
Brigham and Women's Hospital 20
Large-scale testing (Phase 3)Looking for participantsNCT05983783
What this trial is testing

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerChemotherapy Effect
The First Affiliated Hospital with Nanjing Medical University 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07268794
What this trial is testing

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerProstate Cancer (Adenocarcinoma)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fudan University 112
Testing effectiveness (Phase 2)Looking for participantsNCT07190300
What this trial is testing

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals 155
Not applicableActive Not RecruitingNCT06019676
What this trial is testing

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Royal Marsden NHS Foundation Trust 170
Large-scale testing (Phase 3)Looking for participantsNCT03903835
What this trial is testing

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet 750
Not applicableEnrolling By InvitationNCT06865547
What this trial is testing

ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Yonghong Li 94
Testing effectiveness (Phase 2)Looking for participantsNCT07216248
What this trial is testing

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
University of Utah 160
Large-scale testing (Phase 3)Active Not RecruitingNCT04076059
What this trial is testing

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma China, Inc. 180
Early research (Phase 1)Looking for participantsNCT07140900
What this trial is testing

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Amgen 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04720157
What this trial is testing

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Prostatic Neoplasms
Novartis Pharmaceuticals 1,145
Testing effectiveness (Phase 2)Study completedNCT06312670
What this trial is testing

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate CancerProstate Adenocarcinoma
Pedro Barata, MD, MSc 13
Early research (Phase 1)Active Not RecruitingNCT06193993
What this trial is testing

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Who this might be right for
Prostate CancerMetastatic CancerHormone Sensitive Prostate Cancer+1 more
National University Hospital, Singapore 10
Load More Results